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FDG PET/CT Imaging in Carcinoma Oesophagus
Maseeh uz Zaman and Nosheen Fatima
Department of Radiology, Section of NM and PET/CT, The Aga Khan University Hospital, Karachi, Pakistan

Carcinoma of oesophagus is relatively rare malignancy and
constitutes about 10% of all gastrointestinal malignancies. The
5-year survival ranges between 14 - 20%.1,2 Squamous cell
carcinoma (SCC) is the most common pathological variant
rd
(50-70%) and tends to involve the middle and distal 1/3 of
3
oesophagus. Smoking and alcohol consumption are considered important risk factors. While 30-50% cases are adenocarcinoma (AC), which involves distal oesophagus associated with
Barrett's transformation.4 However, in the United States, AC
has become the most common esophageal cancer (about
5
rd
80%). Only 15% of oesophageal cancers involve proximal 1/3
3
of the oesophagus.
Oesophageal cancer has notorious behaviour with dismal
outcome in most of the patients. As oesophagus does not have
serosa, it has the tendency to involve neighbouring structures.
Since oesophagus has a rich vascular and lymphatic supply,
therefore, it has the tendency for an early nodal and distant
metastasis. About 20-30% of patients with carcinoma of
oesophagus present with nodal and (or) distant metastasis at
the time of presentation.6 Early-stage disease is usually asymptomatic; but in the late stage, dysphagia is the most common
presenting complaint. The severity of dysphagia correlates
with a degree of luminal obstruction by primary tumor itself
and/or perilesional nodal metastasis. TNM (tumor, node, metastasis) staging is commonly performed by the American Joint
Committee on Cancer (AJCC - 8th Edition) staging system.7

Fifty-four to sixty-nine percent (54- 69%) of patients with carcinoma of oesophagus are eligible for surgery; however,
median survival after surgery is only 13-19%.8 Neoadjuvant
chemotherapy and external beam radiation therapy are
gaining acceptance in recent years due to promising results.
Conventional diagnostic workup including ﬂuoroscopy,
tomography (CT), MRI and endoscopy ultrasound (EUS) play a
9
pivotal role in diagnosis and staging of the disease.
In the hybrid imaging era, PET/CT using 18-ﬂuorodeoxyglucose
(18FDG) is gaining acceptance in staging, restaging, response
evaluation and prognostication in carcinoma of oesophagus.
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SCC and AC of oesophagus have similar metabolic signatures
18
and concentrate intense FDG uptake. However, the mucinous
type of AC, near the gastro-oesophageal junction, may have
18
slightly less FDG uptake than SCC. The majority of literature
supports the notion that intensity of 18FDG uptake correlates
with survival; and tumors with standardised uptake value <3
(SUVmax <3) are associated with better outcome.10 However,
other prognostic indicators like length of hypermetabolic
primary tumor, regional nodes, and distant metastasis are
strong indicators of survival.
18

FDG PET/CT being a part of diagnostic paradigm in carcinoma
oesophagus has signiﬁcantly improved detection of distant
hypermetabolic metastasis and also speciﬁcity of nodal
staging. Combining 18FDG PET/CT with EUS-guided nodal
biopsy has signiﬁcantly improved diagnostic yield of nodal
18
metastasis prior to surgery. FDG PET/CT has a sensitivity and
speciﬁcity of 51% and 94% for locoregional and 67% and 84%
11
18
for distant staging, respectively. For primary tumor, FDG
PET/CT has an overall sensitivity of 80% which reaches up to
100% for T3 and T4 tumors. However, sensitivity declines to
43% for T1 tumors and fails to detect tumors in situ and T1a
11
18
tumors. Therefore, FDG PET/CT has signiﬁcantly weaker role
in determining T-staging than morphological imaging like CT,
MRI and EUS. For nodal staging, CT/EUS has a sensitivity of 83%
but speciﬁcity of 45%. On the other hand, 18FDG PET/CT has a
sensitivity of 22%, but speciﬁcity of 91% for nodal staging.
Therefore, combining CT/EUS (having good sensitivity) with
18
FDG PET/CT (having good speciﬁcity) would ensure high diagnostic accuracy for nodal staging. For distant metastasis, 18FDG
PET/CT outperforms CT/EUS for being more sensitive (69% vs.
46%) and speciﬁc (93% vs. 74%).11 In clinical practice, 18FDG
PET/CT has been found to change staging in 14% of the patients
and can detect distant hypermetabolic metastasis in additional
5-8% patients, which were not evident on CT/EUS. However, in
patients with recurrence, 18FDG PET/CT has sensitivity and
speciﬁcity similar to morphological imaging (CT/EUS).11
However, use of 18FDG PET/CT in staging of early esophageal
cancers has been questioned by some researchers, as well.12
18

FDG PET/CT is also found to have good predictive value for
response to chemotherapy or chemoradiation.13 18FDG PET/CT
performed two weeks after chemotherapy or chemoradiation
can be used to categorise patients as responder and non-responder, based on metabolic changes (change in SUVmax
pre- and post-therapy scans). Using PET emission response
criteria in solid tumor (PERCIST), signiﬁcant decline in
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SUVmax (30 - 80%) is considered to have better
13
survival. However, due to limited special resolution of PET
images, minimal residual disease cannot be excluded as there
is higher incidence of recurrence within 1-2 years despite
signiﬁcantly reduced SUVmax.
It is important to be cognizant of pitfalls of 18FDGPET/CT imaging.
18
FDG is a sensitive but non-speciﬁc substrate having variable
uptake in malignant and non-malignant (inﬂammatory and infection) lesions.14 Mild diﬀuse 18FDG uptake may be seen in patients
with oesophagitis or lower oesophageal sphincter motility. Similarly, false-positive 18FDG uptake may be seen over hiatus hernia,
benign strictures after dilatation, post-biopsy sites, and
oesophageal leiomyomas. Small intra-capsular nodal metastases have a higher possibility of false negative results. Intense
18
FDG uptake in primary tumor may obscure perilesional nodal
metastatic nodes. Detection of synchronous tumors is not
uncommon (5.5 - 8%) in patients with carcinoma oesophagus
undergoing 18FDG PET/CT study for staging workup.14
Oesophageal cancer is a biologically aggressive and metabolically active tumor with higher mortality. 18FDG PET/CT is useful
for staging, restaging, prognostication, and assessing treatment
response. 18FDG PET/CT has good speciﬁcity for loco-regional
nodal metastases; and being whole-body technique, has good
diagnostic accuracy for distant metastatic disease in patients
with oesophageal cancers. However, 18FDG being a non-speciﬁc
substrate may pose diagnostic challenge due to variable uptake
in malignant and non-malignant (inﬂammatory and infection)
lesions.
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